# HERIZON (NCT02795988)

> A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

No report yet. It can be ordered.

- Drugs tested: IMU-131
- Indication: HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02795988
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Imugene Limited
- Conditions: Gastrointestinal Neoplasms; Adenocarcinoma
- Interventions: IMU-131; Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Enrollment: 64
- Primary outcome: Phase 1b: Number of Participants With Adverse Events (AEs)
- Primary outcome: Phase 2: Overall Survival (OS)
- Primary outcome: Phase 2 Extension: Number of Participants With AEs

## Indexed commentary on HERIZON so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 22
- Podcasts: 4
- YouTube: 1
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=herizon-nct02795988

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02795988", "email": "<work email>"}; the inbox owner confirms by the emailed link.